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 2 
Abstract 
  
Gold nanoparticles (AuNPs) can be used as delivery vehicles for platinum anticancer 
drugs, improving their targeting and uptake into cells.  Here, we examine the 
appropriateness of different sized AuNPs as components of platinum based drug-
delivery systems, investigating their controlled synthesis, reproducibility, consistency 
of drug loading and stability.  The active component of cisplatin was tethered to 25, 
55 and 90 nm AuNPs; with the nanoparticles being almost spherical in nature and 
demonstrating good batch-to-batch reproducibility (24.37 ± 0.62 nm, 55.2 ± 1.75 nm 
and 89.1 ± 2.32 nm).  The size distribution of 25 nm AuNPs has been significantly 
improved, compared with a previous method which produces polydispersed 
nanoparticles.  Attachment of platinum to the AuNP surface through a polyethylene 
glycol (PEG) linker exhibits an increase in drug loading with increasing particle size: 
25 nm (815 ± 106 drug molecules per AuNP); 55 nm (14,216 ± 880); and 90 nm 
(54,487 ± 15,996).  The stability of the naked, PEGylated and platinum conjugated 
nanoparticles has been examined over time under various conditions.  When stored 
at 4 ºC there is minimal variation in diameter for all three AuNP sizes; variation after 
28 days for the 25 nm AuNPs was 2.4%; 55 nm, 3.3%; and 90 nm, 3.6%.  The 25 nm 
AuNPs also demonstrate minimal changes in UV-visible absorbance over the same 
time period.   
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Introduction  
 
Cisplatin, cis-diamminedichloridoplatinum(II), is the leading metallodrug used in the 
systemic treatment of solid tumors.1 Its clinical use is limited by severe toxic side 
effects, attributed to the indiscriminate accumulation of the drug in both normal and 
cancerous tissue, its non-specific interactions with extra- and intracellular proteins, 
and drug resistance, both intrinsic and acquired.2  The focus of drug development is 
now being directed towards delivery vehicles which can overcome these limitations, 
and can specifically target cancerous cells. 
 
Due to the unique disorganised vasculature of cancer cells with numerous pores, 
coupled with compromised lymphatic drainage, nanoparticles can passively target 
solid tumours, leading to an enhanced permeability and retention (EPR) effect.3  This 
EPR effect can be utilised by nanotechnology-based drug delivery as it enhances the 
accumulation of the drug in tumours and minimises uptake by healthy cells.4  For 
optimal efficacy, nanoparticle-based systems must take into consideration the gaps 
in the tumour vasculature endothelium, which can range from 100 nm to 2 µm,5 and 
nanoparticle clearance, which varies with nanoparticle size.6  
  
Gold nanoparticles (AuNPs) are particularly attractive as chemotherapy delivery 
vehicles as they are non-toxic, biocompatible and easily synthesised.7-12  In addition 
to size, their cellular uptake is dependent upon shape and surface charge.13-15 There 
are two important considerations in the endocytosis of gold nanoparticles; the binding 
energy between the ligand and receptor, and the free energy required to drive the 
nanoparticles into the cell.13  Uptake is limited for either extremely small or large 
nanoparticles, with the optimal diameter reported as between 40-60 nm.6, 13-15   
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 4 
We have previously shown that tethering the active component of the platinum 
anticancer drug oxaliplatin to a 20 nm gold nanoparticle via a thiolated PEG linker 
increases cytotoxicity, compared with oxaliplatin alone, and demonstrates nuclear 
penetration.16  Gold nanoparticles and gold nanorods have also been used as 
platforms for the delivery of platinum(IV) prodrugs, demonstrating enhanced cellular 
uptake and superior cytotoxicity compared with cisplatin.17, 18  Cisplatin has been 
loaded onto gold nanoparticles of the form Au-Au2S and Au-Fe3O4 for photodynamic 
thermal therapy and magnetically controlled delivery, respectively.19, 20   
 
Demonstrating that drugs can be tethered to nanoparticles, and that these 
conjugates improve drug uptake and/or activity, is just the first step in the long and 
complex drug approval process.  There are a number of other crucial factors to 
consider which, to our knowledge, for this type of platinum based drug-delivery 
vehicle have yet to be investigated.  Constructing a drug-nanoparticle conjugate with 
reproducible size and shape which demonstrates consistent drug loading, is 
important for its ability to be administered for therapeutic use; i.e., it ensures the 
concentration of delivered drug remains constant.  Stability, both during manufacture 
and storage, must also be established to guarantee that the performance is 
unaffected and the system remains safe. 
 
In this paper we report the construction of platinum tethered gold nanoparticle 
conjugates using the active component of the common anticancer drug cisplatin 
(Figure 1).  This has been achieved for small, medium and large AuNPs (25, 55 and 
90 nm, respectively), where the synthesis shows good reproducibility and 
monodispersity.  The drug-nanoparticle conjugates have been characterised using 
UV-visible spectrometry, dynamic light scattering (DLS), and atomic force microscopy 
(AFM).  The platinum drug was tethered to the AuNPs using a polyethylene glycol 
(PEG) linker, and drug loading was determined using inductively coupled plasma-
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 5 
mass spectrometry (ICP-MS).  Finally, we have determined the effect of platinum 
drug concentration on the stability of the AuNPs during synthesis, as well as 
examining the growth of naked, PEGylated and drug conjugated nanoparticles under 
various conditions.    
 
 
Results and Discussion 
 
Construction of drug-nanoparticle conjugate 
 
The size of a gold nanoparticle can be controlled via the route of synthesis; the Brust-
Schiffrin synthesis involves an organic two-phase reduction and typically yields 
AuNPs 5-6 nm in diameter.21  The Turkevich-Frens method of reducing a gold salt 
with sodium citrate has been reported to produce nanoparticles of 9-120 nm,22  with 
larger nanoparticles in the region of 50-200 nm being produced via the reduction of 
HAuCl4 with hydroquinone in an aqueous solution containing seeds.
23  Our aim was 
to synthesise small, medium and large AuNPs (25, 55 and 90 nm, respectively) 
which demonstrate good reproducibility.  This is a necessity in the construction of a 
drug-delivery vehicle to ensure a consistent drug payload is being administered and 
that the response, whether in vitro or in vivo, can be accurately predicted.   
 
The nanoparticles synthesised in this study have been produced from the reduction 
of sodium tetrachloroaurate(III) by tribasic sodium citrate, where the size of the 
nanoparticles is determined primarily by the pH of the solution, which in turn is 
controlled by the concentration of sodium citrate.24  In this method sodium citrate 
functions as both the nucleating and growth agent,7 as well as distributing a negative 
charge on the nanoparticle surface to minimise aggregation.  A higher citrate 
concentration allows for the stabilisation of smaller particles, while at lower 
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 6 
concentrations, the coverage is incomplete and a coarsening process leads to 
aggregation, producing larger particles.22  These larger nanoparticles have been 
shown to sometimes be polydispersed and yield low particle concentrations.25   
 
Nanoparticles, 25 nm in diameter, were initially synthesised via the established 
citrate reduction method.7, 26  This, however, produced a bimodal size distribution 
curve, as determined by dynamic light scattering (DLS), with peaks at 3.4 and 45.4 
nm (Figure 2).  This is problematic as it is only with monodispersed systems that a 
reliable and precise dosage of drugs can be assured.  A reactant concentration 
study, where we varied the volume of citrate solution, led to the development of a 
new method for synthesising 25 nm AuNPs demonstrating monodispersity (Figure 2) 
and better reproducibility (Table 1).  For both the old method (Turkevich-Frens) and 
our revised method, the concentration (% w/v) of the gold salt and citrate solutions 
remain the same, however, using a 2.7-fold increase in the volume of citrate solution, 
we reproducibly synthesise spherical, monodispersed 25 nm AuNPs. 
 
Table 1.  The reproducibility of 25 nm AuNPs produced by the two synthetic 
methods, where the mean hydrodynamic diameter (z-avg.) and the highest peak from 
the intensity particle size distribution curve (i.e. the relative percentage of light 
scattered by particles of different diameters) were determined by DLS.  Results from 
three batches of AuNPs demonstrate the improved size reproducibility of our revised 
method. 
 
Method 
Average Particle 
Diameter (nm) 
 Highest Intensity 
Peak (nm) 
Turkevich-Frens 17.9 ± 4.1 46.6 ± 4.9 
Revised 22.9 ± 0.6 24.4 ± 0.6 
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 7 
Methods to synthesise 55 and 90 nm gold were also developed and, as expected, 
lower concentrations of citrate were required to produce nanoparticles of these sizes.  
Larger AuNP synthesis method displayed good reproducibility, as observed across 
five batches of AuNPs where small size variations (55.2 ± 1.75 nm and 89.1 ± 2.32 
nm) were observed.  In addition, both the 55 and 90 nm AuNPs were found to show 
improved size uniformity compared with previous synthesis methods.26, 27In 
synthesising the larger AuNPs, it was noted that when the gold salt was not stored in 
a desiccator, there was significant variation in the size of the nanoparticles produced.  
This effect was also observed when water loss from the reaction vessel was not 
minimised, hence affecting the reactant concentration and altering the size of the 
AuNPs produced.  Therefore, when synthesising 55 and 90 nm AuNPs, it is important 
to use an anhydrous gold salt and control water loss through evaporation.     
 
Attachment of the active component of cisplatin, cis-{Pt(NH3)}
2+, to the AuNPs is 
facilitated through a polyethylene glycol (PEG) monolayer.  PEG-based linkers are 
extensively used in the functionalisation of AuNPs as they are stable, non-toxic, 
reduce non-specific binding to proteins and possess good water solubility.28  A large 
number of PEG linkers can be accommodated due to the high surface area of gold 
nanoparticles,29, 30  and in addition to improving stability, circulation time, and cellular 
uptake, they provide an attachment site for drugs and/or cancer targeting groups.28-31  
It has been shown that linkers with multi-thiol anchors, compared with their monothiol 
analogues, show enhanced stability when treated with small molecule 
reducing/displacement agents such as dithiothreitol (DTT).31  PEGylation of the 
AuNPs in this study was accomplished by agitating the linker with nanoparticles at 
appropriate concentrations, as determined by UV-visible spectroscopy and size-
dependent extinction coefficients, overnight.  Experimental parameters for each size 
of gold nanoparticle are given (Table 2). 
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 8 
Table 2.  Experimental parameters for the PEGylation and purification of the three 
different sized AuNPs. 
  
Centrifuge settings Size of 
AuNP 
(nm) 
Concentration of 
AuNP to be 
PEGylated (nM) 
Extinction coefficient,32  
(ε, M-1cm-1) 
Speed 
(RPM) 
Time 
(min) 
25 17 2.7 x108 20 
55 0.17 2.65 x1010 7 
90 0.017 1.346 x1011 
7000 
2 
 
 
The final stage in the assembly of the drug-nanoparticle conjugates was the coupling 
of the platinum drug to the PEGylated AuNPs. To facilitate this, cisplatin was first 
aquated to replace the chloride ligands with the more labile leaving group, water.     
The concentration of drug used in this step was directly adapted from our previous 
study,16 however, for many early batches we found that the nanoparticles turned a 
blue-purple colour upon addition of platinum, measured as a red of λmax of the AuNPs 
or shoulders/additional peaks in the UV-visible spectra (supplementary information).  
This is indicative of AuNP aggregation,33 and in some cases aggregates precipitated 
out of solution and could not be resuspended.  We believe this is a result of the 
decreased surface charge on the nanoparticles as they go from negatively charged 
(from the carboxylate groups on the PEG linker) to neutral.  To eliminate this problem 
and determine maximum platinum loading, concentration studies were performed for 
each of the three different sized nanoparticles, using zeta potential as the measure of 
stability (Figure 3).  The results confirmed our hypothesis; with higher concentrations 
of platinum, a red shift of λmax was observed (data not shown), corresponding with the 
overall AuNP charge approaching zero.   A linear relationship exists between the 
concentration of cis-{Pt(NH3)}
2+ added and zeta potential, a common measurement 
used to indicate stability,34, 35and is dependent upon nanoparticle size (Figure 3).  
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 9 
Aggregation and precipitation occurred at lower platinum concentrations for 55 and 
90 nm AuNPs, and after precipitation zeta potential could not be measured.  Using 
the zeta potential, and the observation of whether the nanoparticles remained in 
solution over time, we have determined the maximum amount of aquated cisplatin 
that can be used in the conjugation of platinum to the AuNPs, which will maintain 
nanoparticle stability: 25 nm, 0.94 x10-12 molecules of platinum; 55 nm, 0.47 x10-12 
moles; and 90 nm, 0.19 x10-12 moles. 
 
 
Nanoparticle Characterisation 
 
The different sized naked, PEGylated and drug-conjugated nanoparticles were 
analysed using a number of techniques to measure particle size, including: UV-
visible spectrometry, atomic force microscopy (AFM) and DLS.  UV-visible 
spectroscopy shows a red shift with increasing particle diameter with a λmax around 
518 nm for the 25 nm AuNPs, which is characteristic of gold nanoparticles around 
this size (Figure 4).36  The 55 and 90 nm AuNPs have a λmax around 528 and 563 nm, 
respectively. 
 
To determine the particle size, the nanoparticles were analysed in the solid state 
using AFM (Figure 5).  The naked AuNPs are roughly spherical in shape, particularly 
the 25 nm AuNPs, with the larger AuNPs showing improved shape distribution 
compared with previous nanoparticles of comparable size synthesised via the 
Turkevich-Frens method.26  Their size correlates well with the results obtained by 
DLS, with the average diameter varying by less than 9%: 24.0 and 25.37 nm; 56.7 
and 55.6 nm; and 97.3 and 89.2 nm (sizes determined by AFM and DLS, 
respectively).  It should be noted that for the 90 nm AuNPs, we would expect the 
hydrodynamic diameter to be larger than that obtained from AFM. 
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The effect of PEGylation and drug conjugation on particle size was also determined 
by AFM and DLS (Figure 5).  The AFM images indicate that there is no significant 
change in the size of the nanoparticles at any stage.  Their hydrodynamic diameter in 
suspension, however, shows an increase in particle size upon PEGylation and drug 
conjugation.  The naked 25 nm AuNPs demonstrate increases from 24.4 nm in size 
to 35.1 and 37.4 nm after PEGylation and platinum conjugation, respectively (Figure 
5).  The hydrodynamic diameter of the 55 nm AuNPs increases from 55.6 nm to 73.2 
and 75.9 nm, and the 90 nm AuNPs from 89.2 nm to 107.2 and 106.0 nm upon 
PEGylation and conjugation, respectively.  The increase in size after PEGylation can 
be used to determine the thickness of the PEG layer;37 however any polydispersity in 
the size distribution makes this difficult.38  The larger hydrodynamic diameters yielded 
by DLS for the latter  two stages of assembly, compared to those observed for the 
naked AuNPs, are due to the interactions between the solvent and the covalently 
surface-bound PEG.  This effect has been previously observed for PEGylated 
AuNPs,39, 40 where hydrodynamic interactions are increased for large PEG linkers.41   
The polymer monolayer is decreasing the mobility of the nanoparticle,42 most likely 
due to solvent interactions. The absence of aggregation when platinum is conjugated 
to the AuNP is an improvement on what we have previously published, where a 4.5-
fold increase in size was observed in both the solution and solid state.16  This is 
because, previously, the platinum drug used was the active component of oxaliplatin, 
{Pt(1R,2R-diaminocyclohexane)}, which has a cyclohexane-based ligand and may 
cause aggregation through hydrophobic self-interactions.  Using the active 
component of cisplatin introduces polar ammine ligands which can hydrogen bond 
with water molecules and help retain stability in solution.   
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Determination of platinum content  
 
The presence of platinum was confirmed by UV-visible spectrometry as spectra 
obtained were of a similar profile to previous studies of cisplatin in water, with a weak 
absorption band which can extend to 350 nm and a sharp increase in absorbance 
between 230 and 250 nm (Figure 6).43  To quantitatively determine the number of 
platinum molecules per nanoparticle, the drug-nanoparticle conjugates were first 
digested using sodium cyanide,44 and subsequently analysed by inductively coupled 
plasma mass spectrometry (ICP-MS).  We have previously been able to demonstrate 
drug loading of up to 300 platinums per AuNP,16 with another study showing up to 
2,812 platinums per AuNP.20   
 
In this study, the drug loading was found to increase significantly with increasing 
particle size: 25 nm (815 ± 106 drug molecules per AuNP); 55 nm (14,216 ± 880); 
and 90 nm (54,487 ± 15,996).  The number of drug molecules conjugated to the 
AuNPs exhibit significant enhancement on all those previously published.  This 
improved, high drug loading is important as it may lead to a significant increase in the 
dose delivered to tumours, especially in the case of the 90 nm drug-nanoparticle 
conjugates.  If the cellular uptake and activity remains unaffected, the higher payload 
will result in increased cytotoxicity, and possibly even overcome some forms of drug 
resistance. 
 
One issue, however, that must be resolved is the variability of the drug loading on the 
nanoparticles: 25 nm, 13%; 55 nm, 6%; and 90 nm, 29%.  
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Nanoparticle Stability  
 
Nanoparticle instability may manifest as agglomeration and/or particle growth, both of 
which result in an increase in the diameter and a red shift of λmax in the case of gold 
nanoparticles.  Maintaining stability over time is essential for the efficacy and safety 
of AuNP-based drugs, as unstable nanosuspensions can affect administration and 
the dose delivered.45 
 
A previous study which investigated the stability of 20 nm AuNPs synthesised via the 
Turkevich-Frens method, highlighted that nanoparticle growth and precipitation from 
solution is an issue.46  When stored at room temperature, the nanoparticles grew up 
to 6.5-fold in size and at 4 ºC, although growth was less than when stored at higher 
temperature, the size of the nanoparticles increased to 40 nm.46   
 
It was therefore of interest to study the stability of our AuNPs.  We have used DLS to 
monitor changes in the hydrodynamic diameter of the nanoparticles over time, at 
room temperature and 4 ºC.  We have examined naked and PEGylated nanoparticles 
and, for the first time, looked at the stability of platinum conjugated AuNPs.  
Compared with the previous study,46 the 25 nm naked AuNPs demonstrate improved 
stability over a four week period, with an average maximum diameter of 33.2 and 
26.3 nm when stored at room temperature and 4 ºC, respectively (Figure 7).  The 
variation in size for the naked nanoparticles after 28 days was 2.4%.   PEGylated and 
drug-conjugated AuNPs also show minimal variation in size at 4 ºC, with the average 
diameter after 28 days demonstrating only a 2.7 and 2.3% increase in size, 
respectively, from the initial measurement (Figure 7).  When stored at room 
temperature, the 25 nm nanoparticles increase by 4.0 and 15.6% in size for the 
PEGylated and drug-conjugated nanoparticles.  The growth of the nanoparticles is 
therefore dependent upon storage conditions and so, to maintain stability over time, 
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they should be stored at 4 ºC.  The minimised growth at this temperature is 
postulated to be because at the higher temperature, there is more kinetic energy to 
encourage agglomeration, which results in larger particle sizes.46   
 
As minimised growth was observed at 4 ºC for the 25 nm AuNPs, it was this 
temperature at which the stability of 55 and 90 nm AuNPs was examined.  For either 
size, minimal growth is observed, regardless of whether the nanoparticles are naked, 
PEGylated or drug-conjugated (not shown).  For the naked nanoparticles, the 
variation in average diameter after 28 days was 3.3 and 3.6%, for the 55 and 90 nm 
AuNPs, respectively.   The results from the three different sized AuNPs show that the 
drug-conjugated nanoparticles exhibit enhanced stability compared with the previous 
two stages of assembly. 
 
We also examined changes in UV-visible absorbance of the 25 nm AuNPs.  This 
technique was used to assess AuNP stability as decreases in λmax may have 
indicated that aggregation had occurred and/or the nanoparticles had precipitated.  
There were no drastic changes in absorbance, except for the PEGylated 
nanoparticles when stored at room temperature (Figure 7).  The drop in 
concentration of the PEGylated AuNPs reinforces our earlier conclusion that gold 
nanoparticles should be stored at low temperatures.   
 
This investigation has established that the method we have developed for AuNP 
synthesis produces naked nanoparticles which are relatively stable over time.  We 
have also demonstrated that when stored at low temperatures, 25-, 55- and 90 nm-
naked, PEGylated and drug-conjugated AuNPs exhibit a smaller degree of size 
variation over time.   
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Conclusions 
 
For any new drug to get approval for human clinical trials, it must demonstrate not 
only efficiency, but also be able to be reproducibly manufactured and stored in a 
stable manner, whether the formulation is in solid form or an aqueous suspension.  
Previously we, and others, have shown that platinum drugs can be conjugated to 
AuNPs and that cellular uptake and cytotoxicity are significantly improved.  To further 
develop AuNPs as platinum drug-delivery vehicles, it was essential to establish their 
level of reproducibly and stability.  Here, we have reported a revised method for 
producing AuNPs that displays better size distribution and reproducibility for 25 nm 
AuNPs.  For 55 and 90 nm AuNPs, the method shows improved nanoparticle shape 
and good reproducibility.  Subsequent conjugation of the nanoparticles with the 
active component of cisplatin, cis-{Pt(NH3)}
2+, showed enhanced drug loading, with 
the number of platinums per nanoparticle ranging from 700 to 70,000.  An issue 
which must be addressed in the future, however, is the variability of the drug loading 
on each of the AuNP sizes.  During drug conjugation, an increase in the 
concentration of cis-{Pt(NH3)}
2+ led to an increase the overall charge of the 
nanoparticle, representative of the nanosuspension becoming unstable.  Additionally, 
it has previously been shown that AuNPs can grow and/or aggregate when stored as 
suspensions.  We have found that storage at 4 ºC and drug-conjugation of the 
nanoparticles improves their stability so they can be stored for several weeks without 
significant change.  Overall, these results provide an important next step in the 
development of AuNPs as delivery vehicles for platinum drugs.  To move forward, a 
large scale synthetic method should be developed so that AuNPs and their drug 
conjugates can be fully examined in vitro and in vivo.  
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Methods 
 
Materials.  All chemicals and solvents used were purchased from Sigma-Aldrich.  All 
aqueous solutions were prepared using water filtered by a Millipore purification unit.  
The synthesis of aquated cisplatin followed a published method,47 as did the 
synthesis of the polyethylene glycol (PEG) linker.16 
 
Inductively coupled plasma – mass spectrometry.  Before analysis, gold 
nanoparticles were digested into gold ions using a standard method of dissolution 
with sodium cyanide.44  An Agilent 7700X instrument, with a micromist nebuliser and 
an octapole collision cell, was calibrated using solutions prepared from a Spex 
CertPrep platinum standard at concentrations ranging from 0 – 1000 ppb, containing 
2% nitric acid.  The platinum drug concentration on the AuNPs was determined using 
the 195Pt isotope.  Instrument operating conditions used were 1,550W RF forward 
power, 0.85 L min-1 plasma carrier gas flow, 0.2 L min-1 makeup gas flow, 4.6 mL 
min-1 helium gas flow in the collision cell and 0.1 rps for the nebulizer pump.  Sample 
depth was 8 mm, sample period was 0.31 s and integration time was 0.1 s. 
 
Dynamic light scattering. Dynamic light scattering and zeta potential experiments 
were conducted on a Malvern Zetasizer Nano ZS. The machine was calibrated using 
a 60 nm polystyrene standard. A 1 mL sample was loaded into a cell and the particle 
size and zeta potential were measured simultaneously 3 times with triplicate 
samples. 
 
Atomic Force Microscopy.  A gold nanoparticle suspension (5 µL) was deposited 
onto a freshly cleaved mica surface (G250-2 Mica sheets 2.54 cm x 2.54 cm x 0.015 
cm; Agar Scientific Ltd, Essex, UK), and air dried for 30 min. The images were 
obtained by scanning the mica surface in air under ambient conditions using a Bruker 
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MultiMode with NanoScope IIID Controller Scanning Probe Microscope (Digital 
Instruments, Santa Barbara, CA, USA; Bruker software Version 6.14r1) operated in 
tapping mode. The AFM measurements were obtained using sharp silicon probes 
(TESP; nominal length (lnom) = 125 µm, width (wnom) = 40 µm, tip radius (Rnom) = 
8 nm, resonant frequency (υnom) = 320 kHz, spring constant (knom) = 42 N m-1 
(Bruker Instruments SAS, Dourdan, France). AFM scans were taken at 512 x 512 
pixels resolution and produced topographic images of the samples in which the 
brightness of features increases as a function of height. Typical scanning parameters 
were as follows: tapping frequency 322 kHz, integral and proportional gains 0.4 and 
0.6, respectively, set point 0.4 – 0.6 V and scanning speed 1.0 Hz.  AFM images 
were collected from two different samples and at random spot surface sampling (at 
least five areas). 
 
Ultraviolet-visible spectroscopy.  UV-visible spectra were obtained using a Varian 
Cary 50 Bio spectrophotometer running Cary WinUV scan software.  Each sample (2 
mL) was prepared at appropriate dilutions to achieve absorption values between 0 – 
1.  Samples were examined in a silica cuvette (1 cm) and an average of three 
measurements was used. 
 
Synthesis of naked gold nanoparticles. All glassware used in the preparation of 
nanoparticles was soaked in aqua regia (3:1 HCl:HNO3) for at least 4 h and then 
rinsed with distilled water until the water pH was neutral.  NaAuCl4.2H2O (50 mg, 
0.14 mmol) was dissolved in a three neck round bottom flask using distilled water 
(500 mL).  This was heated using a bunsen burner to 100 °C with continuous stirring 
by a double linked glass stirrer using a mechanical stirrer (Janke & Kunkel, Type 
RW20, speed setting “5.5”). Each neck of the flask was sealed with tinfoil to minimise 
loss of water by evaporation.  Upon boiling, a fresh room temperature solution of 
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sodium citrate was added to achieve the desired size of nanoparticle (1% m/v stock 
solution: 25 nm, 20 mL; 55 nm, 3.7 mL; 90 nm, 2.1 mL).  The solution was 
continuously boiled and stirred for 15 min before cooling to room temperature while 
stirring at a reduced speed (speed setting “2”).  The colloid was concentrated by 
centrifuge (25 nm, 6000 rpm/2 h;  55 nm, 4000 rpm/ 20 min;  90 nm, 4000 rpm/10 
min) and the supernatant liquid removed by decanting. 
 
Assembly of platinum tethered nanoparticles. To an eppendorf vessel containing 
gold nanoparticles (1 mL: 25 nm, 17 nM; 55 nm, 0.17 nM; 90 nm, 0.017 nM), PEG 
linker was added (100 µL, 1 mM) and agitated for 4h by placing in a round bottom 
flask and spinning on a rotary evaporator.  Unbound PEG linker was removed by 
centrifuging (7000 rpm: 25 nm, 20 min; 55 nm, 7 min; 90nm, 2 min), the supernatant 
liquid removed and the remaining pellet resuspended in water (1 mL). The washing 
process was repeated once more before N,N-diisopropylethylamine (100 µL, 0.1 
mM) was added to the nanoparticles. This was followed by the addition of 25 µL of a 
cis-[Pt(OH2)2(NH3)2]2NO3 dissolved in 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-
pyrimidone stock solution (25 nm, 10 mg/mL; 55 nm, 5 mg/mL; 90 nm, 2 mg/mL), and 
the nanoparticle left agitating overnight.  Finally, the gold nanoparticles were 
centrifuged (same conditions as for the purification of PEGylated nanoparticles, 
Table 2), the supernatant liquid was removed and the remaining pellet resuspended 
in water (1 mL) before the wash was repeated once more. 
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Figure 1.  The drug-nanoparticle conjugate where the AuNP is functionalised with a 
polyethylene glycol (PEG) linker through a cyclic disulfide anchor and tethered to the 
active component of the anticancer drug cisplatin via the terminal carboxylate groups. 
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Figure 2.  Dynamic light scattering spectra showing the diameter and distribution of 
25 nm AuNPs synthesised via the established Turkevich-Frens method,7, 26 (peaks at 
3.4 and 45.4 nm) and our revised method, the latter showing monodispersity (peak 
average of 24.4 nm). 
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Figure 3.  A graph showing the effect of platinum concentration on the charge of 
different sized AuNPs after drug conjugation: 25 nm (purple, r2 = 0.9926); 55 nm 
(green, r2 = 0.9318); and 90 nm (r2 = 0.9567).  For each size, the concentration of 
aquated cisplatin above which significant nanoparticle aggregation occurs is 
highlighted. 
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Figure 4. UV-visible spectra of the three different sized AuNPs: 25 nm (purple, λmax = 
518 nm); 55 nm (green, λmax = 528 nm); and 90 nm (orange, λmax = 563 nm), showing 
the expected red shift with increasing nanoparticle size.   
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Figure 5.  Atomic force microscopy images of the 25, 55 and 90 nm naked, 
PEGylated and drug conjugated AuNPs, showing the particle size as determined by  
AFM, and their hydrodynamic diameter (in brackets) obtained by DLS.  An increase 
in the hydrodynamic diameter is observed upon PEGylation and platinum 
conjugation: 25nm, 44 and 52% (PEGylated and conjugated, respectively); 55nm, 32 
and 37%; and 90 nm, 20 and 19%. 
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Figure 6.  UV-visible spectra of PEGylated-only (dashed) and platinum-loaded (solid) 
AuNPs: 25 nm (purple), 55 nm (green) and 90 nm (orange).  A red shift is observed 
compared with naked AuNPs (Figure 4) and on tethering the active component of 
cisplatin to the AuNPs, a sharp increase in absorbance is observed around 230 nm. 
Absorbance has been removed to stack spectra clearly.   
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Figure 7.  The stability of 25 nm AuNPs at each stage of assembly when stored at 
room temperature (purple) and at 4 ºC (green), with day 1 representing the day of 
synthesis.  The bar chart represents the nanoparticle diameter in nanometres, as 
measured by DLS (left axis), and the line graph is nanoparticle absorbance, as 
measured by UV-Vis (right axis).  
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Table of contents graphic 
 
In this paper we have examined the synthesis, reproducibility, drug loading and 
stability of gold nanoparticles and analysed them as they relate to their use as 
delivery vehicles for platinum-based anticancer drugs. 
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